Castle Biosciences Expects 2025 Revenue to Exceed $340 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: Globenewswire
- Significant Revenue Growth: Castle Biosciences anticipates total revenue for 2025 to exceed $340 million, surpassing the previously guided range of $327-335 million, reflecting strong performance in its innovative test portfolio and bolstering confidence in future growth.
- Surge in Core Test Reports: Total test reports for core revenue drivers increased by 37% in 2025 compared to 2024, with DecisionDx-Melanoma reports reaching 39,083 and TissueCypher reports at 39,014, indicating a robust recovery in market demand.
- Successful New Test Launch: The limited access launch of AdvanceAD-Tx in November 2025 saw over 50% of 150 clinician offices placing orders within the first five weeks, demonstrating rapid market acceptance and further expanding the company's total addressable market.
- Strong Financial Position: Year-end 2025 cash and cash equivalents are expected to be approximately $300 million, alongside $184 million in marketable investment securities, showcasing a solid financial foundation that provides ample funding for future expansion and innovation.
Analyst Views on CSTL
Wall Street analysts forecast CSTL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSTL is 34.39 USD with a low forecast of 23.56 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 40.750
Low
23.56
Averages
34.39
High
41.00
Current: 40.750
Low
23.56
Averages
34.39
High
41.00
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
